Colonial Trust’s Immunogen Inc IMGN Stock Holding History

Colonial Trust’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-129	Closed	-$666	–	946
2022 Q4	$666	Buy	+129	New	+$699	﹤0.01%	885

Other funds holding IMGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Colonial Trust's IMGN Position: Q1 2023 in Review

Colonial Trust sold out of Immunogen Inc (IMGN) in Q1 2023, closing a stake of 129 shares — an estimated $666 sold.

Colonial Trust first reported a position in IMGN in Q4 2022 and held it in 1 quarter. The position peaked at $666 in Q4 2022. 190 funds tracked by Wall St. Rank hold IMGN as of Q1 2023.

Colonial Trust reported no remaining Immunogen Inc position as of Q1 2023 after selling out during the quarter.
Colonial Trust sold 129 Immunogen Inc shares in Q1 2023, an estimated $666.
Colonial Trust first reported a position in Immunogen Inc in Q4 2022 and held it in 1 quarter.
Colonial Trust's Immunogen Inc position peaked at $666 in Q4 2022.
190 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2023.

Based on Colonial Trust's 13F filing for Q1 2023, filed 11 May 2023.